AU2590901A - Il-17 homologous polypeptides and therapeutic uses thereof - Google Patents

Il-17 homologous polypeptides and therapeutic uses thereof

Info

Publication number
AU2590901A
AU2590901A AU25909/01A AU2590901A AU2590901A AU 2590901 A AU2590901 A AU 2590901A AU 25909/01 A AU25909/01 A AU 25909/01A AU 2590901 A AU2590901 A AU 2590901A AU 2590901 A AU2590901 A AU 2590901A
Authority
AU
Australia
Prior art keywords
polypeptides
present
therapeutic uses
homologous polypeptides
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25909/01A
Other languages
English (en)
Inventor
Jian Chen
Ellen Filvaroff
Sherman Fong
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Kenneth J. Hillan
Hanzhong Li
Daniel Tumas
Menno Van Lookeren
Richard L Vandlen
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Daniel G. Yansura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/031274 external-priority patent/WO2000053752A2/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/007532 external-priority patent/WO2000070050A1/en
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2590901A publication Critical patent/AU2590901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
AU25909/01A 1999-12-23 2000-12-20 Il-17 homologous polypeptides and therapeutic uses thereof Abandoned AU2590901A (en)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US17209699P 1999-12-23 1999-12-23
US60172096 1999-12-23
WOUS99/31274 1999-12-30
PCT/US1999/031274 WO2000053752A2 (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization
US17548100P 2000-01-11 2000-01-11
US60175481 2000-01-11
WOUS00/04341 2000-02-18
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
WOUS00/05841 2000-03-02
US19100700P 2000-03-21 2000-03-21
PCT/US2000/007532 WO2000070050A1 (en) 1999-05-14 2000-03-21 Compositions and methods for the treatment of immune related diseases
US60191007 2000-03-21
WOUS00/07532 2000-03-21
PCT/US2000/015264 WO2000073452A2 (en) 1999-06-02 2000-06-02 Compositions and methods for the treatment of immune related diseases
WOUS00/15264 2000-06-02
US21380700P 2000-06-22 2000-06-22
US60213087 2000-06-22
US64484800A 2000-08-22 2000-08-22
US09644848 2000-08-22
WOUS00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US24283700P 2000-10-24 2000-10-24
US60242837 2000-10-24
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
WOUS00/30873 2000-11-10
US25364600P 2000-11-28 2000-11-28
US60253646 2000-11-28
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOUS00/32678 2000-12-01
PCT/US2000/034956 WO2001046420A2 (en) 1999-12-23 2000-12-20 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU2590901A true AU2590901A (en) 2001-07-03

Family

ID=40140243

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25909/01A Abandoned AU2590901A (en) 1999-12-23 2000-12-20 Il-17 homologous polypeptides and therapeutic uses thereof

Country Status (10)

Country Link
EP (1) EP1240325B1 (enExample)
JP (10) JP5070117B2 (enExample)
AT (5) ATE537258T1 (enExample)
AU (1) AU2590901A (enExample)
CA (1) CA2391374A1 (enExample)
CY (1) CY1112334T1 (enExample)
DK (1) DK1240325T3 (enExample)
ES (7) ES2380958T3 (enExample)
PT (4) PT1897945E (enExample)
WO (1) WO2001046420A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
WO2001064240A2 (en) * 2000-02-29 2001-09-07 Zymogenetics, Inc. Methods for promoting production of myelin by schwann cells
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
CA2406245A1 (en) * 2000-04-18 2001-10-25 Schering Corporation Il-174 uses, compositions and methods
WO2001090358A2 (en) * 2000-05-24 2001-11-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2427824A1 (en) * 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
EP1529843A3 (en) * 2000-08-11 2005-06-08 Eli Lilly & Company Novel secreted proteins and their uses
ATE349523T1 (de) * 2000-10-13 2007-01-15 Lilly Co Eli Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
AU2002225714A1 (en) * 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20050089957A1 (en) * 2001-10-19 2005-04-28 Audrey Goddard Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU2003267096B9 (en) * 2002-09-11 2010-11-11 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2011516026A (ja) * 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
CA2518101A1 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
DK2784084T4 (da) 2003-07-08 2024-01-08 Novartis Pharma Ag Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
DK1983000T3 (en) 2003-11-21 2015-12-07 Ucb Biopharma Sprl A method for the treatment of multiple sclerosis by inhibiting IL-17 activity
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
AU2005254998B2 (en) 2004-06-10 2011-10-27 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
ES2324306T3 (es) * 2004-09-21 2009-08-04 Merck Serono Sa Uso de il-17f para el tratamiento y/o la prevencion de enfermedades neurologicas.
JP2009505967A (ja) * 2005-08-04 2009-02-12 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ｂを用いた創傷の処置方法
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
CA2638819A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
EP2089050A2 (en) * 2006-11-08 2009-08-19 Zymogenetics, Inc. Il- 17b for use in wound healing
MX2009010273A (es) 2007-03-26 2009-10-12 Zymogenetics Inc Proteinas de fusion il-17ra/rc solubles y metodos relacionados.
US20090317400A1 (en) 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
GB0905972D0 (en) * 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
EP2665750A1 (en) 2011-01-17 2013-11-27 Novo Nordisk A/S Il-21 ligands
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
RS57209B1 (sr) * 2011-10-19 2018-07-31 Morphosys Ag Antagonisti il17c za lečenje zapaljenskih poremećaja
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
KR20150050921A (ko) * 2013-11-01 2015-05-11 현대중공업 주식회사 폐열 회수용 연관식 보일러
EP3212665A2 (en) 2014-10-31 2017-09-06 F. Hoffmann-La Roche AG Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO1996029408A1 (en) * 1995-03-23 1996-09-26 Immunex Corporation Il-17 receptor
WO1999060127A2 (en) * 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
WO2000070050A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1258315A (zh) * 1997-04-25 2000-06-28 津莫吉尼蒂克斯公司 哺乳动物细胞因子样因子7
EP1012260A4 (en) * 1997-07-16 2001-05-09 Human Genome Sciences Inc INTERLEUKINE-20
DE69841140D1 (de) * 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO1999032632A1 (en) * 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
NZ507435A (en) * 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
CA2361204A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
AU3207000A (en) * 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
AU2596700A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU6069800A (en) * 1999-07-07 2001-01-30 Zymogenetics Inc. Human cytokine receptor
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途

Also Published As

Publication number Publication date
PT1897944E (pt) 2011-11-28
DK1240325T3 (da) 2010-01-25
JP2015077137A (ja) 2015-04-23
ES2379101T3 (es) 2012-04-20
JP2010266454A (ja) 2010-11-25
ES2506665T3 (es) 2014-10-13
ATE519847T1 (de) 2011-08-15
WO2001046420A8 (en) 2002-07-04
ES2458349T3 (es) 2014-05-05
ATE444361T1 (de) 2009-10-15
JP5070117B2 (ja) 2012-11-07
ES2388748T3 (es) 2012-10-18
ATE541930T1 (de) 2012-02-15
WO2001046420A2 (en) 2001-06-28
HK1150856A1 (en) 2012-01-13
PT1897945E (pt) 2012-03-29
JP2008278887A (ja) 2008-11-20
WO2001046420A3 (en) 2002-05-10
PT1240325E (pt) 2010-01-07
HK1114637A1 (en) 2008-11-07
HK1114635A1 (en) 2008-11-07
ATE541931T1 (de) 2012-02-15
ATE537258T1 (de) 2011-12-15
JP2013165712A (ja) 2013-08-29
JP2015007091A (ja) 2015-01-15
JP5258691B2 (ja) 2013-08-07
EP1240325A2 (en) 2002-09-18
JP2012115275A (ja) 2012-06-21
JP2009159968A (ja) 2009-07-23
ES2333772T3 (es) 2010-03-01
CY1112334T1 (el) 2015-12-09
PT1897947E (pt) 2012-03-29
JP2009278996A (ja) 2009-12-03
EP1240325B1 (en) 2009-09-30
ES2380812T3 (es) 2012-05-18
ES2380958T3 (es) 2012-05-21
CA2391374A1 (en) 2001-06-28
JP2014239685A (ja) 2014-12-25
HK1114636A1 (en) 2008-11-07
JP2012152218A (ja) 2012-08-16
HK1114638A1 (en) 2008-11-07
HK1114634A1 (en) 2008-11-07

Similar Documents

Publication Publication Date Title
AU2590901A (en) Il-17 homologous polypeptides and therapeutic uses thereof
AU3774300A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999060127A3 (en) Il-17 homologous polypeptides and therapeutic uses thereof
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
WO1999061469A3 (en) Prostate growth-associated membrane proteins
EP1669371A3 (en) Composition and methods for the diagnosis of tumours
WO1999028462A3 (en) Polypeptides and nucleic acids encoding the same
MXPA01002592A (es) Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2000039297A3 (en) Il-1 related polypeptides
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP1241179A3 (en) Human cornichon-like protein and nucleic acids encoding it
EP1666594A3 (en) Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
EP1251139A3 (en) Human mindin-like protein and nucleic acids encoding it
EP1159421B8 (en) Human suppressor of fused
EP1247817A3 (en) Human CD23-like protein and nucleic acids encoding it
EP1241252A3 (en) Human enteropeptidase-like protein and nucleic acids encoding it
EP2290081A3 (en) IL-17 homologous polypeptide and therapeutic uses thereof
EP1241251A3 (en) Human prostasin-like protein and nucleic acids encoding the same
EP1283215A3 (en) Secreted polypeptide and nucleic acids encoding it
EP1241180A3 (en) Human A33 antigen-like protein and nucleic acids encoding it
EP1241187A3 (en) Fibilin-like polypeptide and nucleic acids encoding the same
EP1241250A3 (en) Human dehydrogenase-like protein and nucleic acid encoding it
EP1300417A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase